why CFL?

Our experience has shown that the more unique the fragment defined space, the more unique, i.e. patentable, molecules can be developed. In addition, the more desirable properties the fragments possess, the better quality preclinical leads can be developed from them with greater chances for clinical success.


The first drug designed using Fragment-Based Lead Discovery, Vemurafenib (Zelboraf), received FDA approval for the treatment of late-stage meianoma in August 2011.

          Vemurafenib

          Vemurafenib



CFL